Strongbridge Biopharma (NASDAQ:SBBP) was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating in a research report issued on Monday.
SBBP has been the topic of several other research reports. Laidlaw assumed coverage on shares of Strongbridge Biopharma in a research note on Tuesday, December 18th. They set a “buy” rating and a $11.00 price objective on the stock. Zacks Investment Research lowered shares of Strongbridge Biopharma from a “hold” rating to a “sell” rating in a research note on Wednesday, November 7th. Finally, Cantor Fitzgerald set a $17.00 price objective on shares of Strongbridge Biopharma and gave the stock a “buy” rating in a research note on Wednesday, October 31st. Two analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $14.13.
NASDAQ:SBBP opened at $4.73 on Monday. Strongbridge Biopharma has a one year low of $3.82 and a one year high of $9.25. The company has a debt-to-equity ratio of 8.76, a quick ratio of 3.11 and a current ratio of 3.38. The stock has a market cap of $221.87 million, a P/E ratio of -3.26 and a beta of 0.15.
In other Strongbridge Biopharma news, major shareholder Associates L.L.C. Cdk acquired 146,467 shares of the company’s stock in a transaction that occurred on Thursday, December 20th. The shares were acquired at an average price of $4.00 per share, with a total value of $585,868.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 4.20% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Alps Advisors Inc. lifted its stake in shares of Strongbridge Biopharma by 25.1% in the third quarter. Alps Advisors Inc. now owns 82,657 shares of the biotechnology company’s stock worth $401,000 after buying an additional 16,574 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Strongbridge Biopharma in the second quarter worth approximately $130,000. Jane Street Group LLC bought a new position in shares of Strongbridge Biopharma in the second quarter worth approximately $154,000. California Public Employees Retirement System bought a new position in shares of Strongbridge Biopharma in the second quarter worth approximately $185,000. Finally, Citadel Advisors LLC bought a new position in shares of Strongbridge Biopharma in the third quarter worth approximately $157,000. Hedge funds and other institutional investors own 65.68% of the company’s stock.
About Strongbridge Biopharma
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada.
Further Reading: How to Profit and Limit Losses With Stop Orders
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.